24/02/2026 – AB Science announced the identification of a potential biomarker for assessing the activity of masitinib in pathological microglial involvement in Amyotrophic Lateral Sclerosis (ALS) Download PDF Category: 202624 February 2026Post navigationPreviousPrevious post:FDA granted the status of Minor Use in Major Species (MUMS) for Masivet®NextNext post:Update on clinical development programRelated PostsAB Science web conference of October 14, 202614 October 2026Web conference on October 14, 2026, from 6:00 p.m. to 7:30 p.m.12 October 2026Revenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
